

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
06 September 2024 (06.09.2024)



(10) International Publication Number  
**WO 2024/180262 A1**

(51) International Patent Classification:

A61K 39/118 (2006.01) C07K 14/295 (2006.01)  
A61P 31/04 (2006.01)

(21) International Application Number:

PCT/EP2024/055631

(22) International Filing Date:

04 March 2024 (04.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

|            |                             |    |
|------------|-----------------------------|----|
| 63/449,571 | 02 March 2023 (02.03.2023)  | US |
| 23305375.0 | 20 March 2023 (20.03.2023)  | EP |
| 63/500,393 | 05 May 2023 (05.05.2023)    | US |
| 23306372.6 | 11 August 2023 (11.08.2023) | EP |

(71) Applicant: **SANOFI** [FR/FR]; 46 Avenue de la Grande Armée, 75017 Paris (FR).

(72) Inventors: **ARNAUD BARBE, Nadege**; c/o Sanofi, Patent Department, 46 Avenue de la Grande Armée, 75017 Paris (FR). **COLE, Leah**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **KARLSSON, Andreas**; c/o Sanofi, Patent Department, 46 Avenue de la Grande Armée, 75017 Paris (FR). **SANCHEZ, Violette**; c/o Sanofi, Patent Department, 46 Avenue de la Grande Armée, 75017 Paris (FR). **TIBBITTS, Timothy**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **HOLLAND, David Christopher** et al.; Carpmals & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))  
— with sequence listing part of description (Rule 5.2(a))

WO 2024/180262 A1

(54) Title: COMPOSITIONS FOR USE IN TREATMENT OF CHLAMYDIA

(57) Abstract: This invention relates to compositions (e.g., vaccine compositions) which can be used to immunise against *Chlamydia* infections. The compositions comprise *Chlamydia* sp. antigens and antigen combinations which can be used to immunise against *Chlamydia* sp., used in the form of nucleic acids (e.g., mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.